Bristol Myers Squibb Co (BMY) Cash & Equivalents (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Cash & Equivalents for 18 consecutive years, with $8.7 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents fell 30.77% year-over-year to $8.7 billion; the TTM figure through Jun 2026 stood at $8.7 billion (down 30.77% YoY), while the FY2025 annual figure was $10.2 billion, down 1.32% from the prior year.
• Cash & Equivalents declined to $8.7 billion in Q2 2026 per BMY's latest filing, from $9.6 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $15.7 billion in Q3 2025 and bottomed at $6.3 billion in Q2 2024.
• Historically, Cash & Equivalents has averaged $9.9 billion across 5 years, with a median of $9.5 billion in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 42.88% — and 2025, when it jumped 100.21%.
• Bristol Myers Squibb's Cash & Equivalents stood at $9.1 billion in 2022, then gained by 25.66% to $11.5 billion in 2023, then fell by 9.75% to $10.3 billion in 2024, then dropped by 1.32% to $10.2 billion in 2025, then slipped by 14.57% to $8.7 billion in 2026.
• Business Quant data shows BMY's Cash & Equivalents at $8.7 billion in Q2 2026, $9.6 billion in Q1 2026, and $10.2 billion in Q4 2025.